Monashee Investment Management logo

Monashee Investment Management

North America, Massachusetts, United States, Boston

Description

Monashee Investment Management LLC is a Boston-based hedge fund founded in 2008 by Patrick O'Shaughnessy and Michael O'Shaughnessy. The firm specializes in a long/short equity strategy, primarily investing in publicly traded securities across various sectors. Their investment philosophy hinges on rigorous fundamental research to identify mispriced assets, aiming to generate absolute returns irrespective of broader market movements. Monashee's portfolio often features a concentrated selection of companies, reflecting high conviction in their chosen positions.

As a hedge fund, Monashee's operational model differs significantly from that of a venture capital firm. Their primary focus is on managing capital within public markets, utilizing strategies such as short selling and derivatives in addition to long positions in equities. Regulatory filings, such as their Form 13F submissions to the SEC, consistently demonstrate their engagement with liquid public securities. For instance, their Q4 2023 filing revealed managed public equity assets exceeding $1.5 billion, spread across approximately 41 distinct equity positions. This indicates a focus on established, publicly traded companies rather than early-stage private ventures.

Consequently, the concept of "first cheque size" – a standard metric for venture capital investments into nascent startups – does not apply to Monashee Investment Management's core business. They do not operate as an early-stage investor providing seed or Series A funding. While some hedge funds may occasionally participate in private investment rounds, these are typically later-stage or pre-IPO opportunities, and not analogous to the initial funding rounds provided by venture capitalists. Therefore, typical "check sizes" for venture capital investments are not a relevant or discoverable aspect of Monashee's investment strategy.

Investor Profile

Monashee Investment Management has backed more than 29 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 3% of its total and boasts 16 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Post Ipo Equity, Series C, Series B rounds (top funding stages).
  • Majority of deals are located in United States, United Kingdom, Switzerland.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.

Stage Focus

  • Post Ipo Equity (41%)
  • Series C (24%)
  • Series B (17%)
  • Series A (7%)
  • Series D (7%)
  • Convertible Note (3%)

Country Focus

  • United States (86%)
  • United Kingdom (10%)
  • Switzerland (3%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Medical Device
  • Life Science
  • Genetics
  • Health Diagnostics
  • Pharmaceutical
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Monashee Investment Management frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 4
OrbiMed
North America, New York, United States, New York
Co-Investments: 5
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 4
Farallon Capital Management
North America, California, United States, San Francisco
Co-Investments: 4
CA
North America, Massachusetts, United States, Boston
Co-Investments: 5
Deerfield
North America, New York, United States, New York
Co-Investments: 4
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 4
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 4
Invus
North America, New York, United States, New York
Co-Investments: 5
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 5

Which angels does Monashee Investment Management often collaborate with?

SB
North America, California, United States
Shared Deals: 1
JD
North America, California, United States, Palo Alto
Shared Deals: 1
DB
North America, Illinois, United States, Chicago
Shared Deals: 1
JG
North America, California, United States, San Francisco
Shared Deals: 1
JT
Europe, Harjumaa, Estonia, Tallinn
Shared Deals: 1
JR
North America, California, United States, San Francisco
Shared Deals: 1
LA
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by Monashee Investment Management?

Pepgen

Oxford, Oxfordshire, United Kingdom

PepGen is empowering nucleic acid therapeutics to go the distance.

BiotechnologyClinical TrialsMedical
Post Ipo EquityFeb 7, 2024
Amount Raised: $80,100,000
Compass Therapeutics, Inc.

Boston, Massachusetts, United States

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

BiopharmaBiotechnologyTherapeutics
Post Ipo EquityNov 2, 2022
Amount Raised: $80,000,000
Gossamer Bio

San Diego, California, United States

Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityJul 13, 2022
Amount Raised: $120,000,000
MoonLake Immunotherapeutics

Zug, Zug, Switzerland

MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.

Biotechnology
Post Ipo EquityApr 6, 2022
Amount Raised: $115,000,000
Scipher Medicine

Waltham, Massachusetts, United States

Scipher Medicine develops a healthcare platform designed to determine which drug will work best for each patient.

Alternative MedicineBiotechnologyGeneticsHealth CareHealth Diagnostics
Series DFeb 24, 2022
Amount Raised: $110,000,000
AN2 Therapeutics

Menlo Park, California, United States

AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.

BiotechnologyHealth CarePharmaceutical
Series BJan 7, 2022
Amount Raised: $80,000,000
Korro Bio

Cambridge, Massachusetts, United States

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

BiotechnologyHealth CarePharmaceutical
Series BJan 5, 2022
Amount Raised: $116,000,000
Pardes Biosciences

Carlsbad, California, United States

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus.

BiotechnologyLife Science
Post Ipo EquityDec 27, 2021
Amount Raised: $75,000,000
Quell Therapeutics

London, England, United Kingdom

Quell Therapeutics is a cell therapy company

AssociationBiotechnologyEducationHealth Care
Series BNov 29, 2021
Amount Raised: $156,000,000
HotSpot Therapeutics

Boston, Massachusetts, United States

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.

BiopharmaBiotechnologyHealth CareLife ScienceTherapeutics
Series CNov 29, 2021
Amount Raised: $100,000,000